Search
Brinzolamide
go.drugbank.com/drugs/DB01194ApprovedBrinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase II (CA-II) inhibitor indicated to reduce ocular pressure in patients with ocular hypertension or open-angle glaucoma. Although the exact pathophysiology of...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesZopiclone
go.drugbank.com/drugs/DB01198ApprovedInvestigationalZopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbitu...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesFomepizole
go.drugbank.com/drugs/DB01213ApprovedVet approvedFomepizole is used as an antidote in confirmed or suspected methanol or ethylene glycol poisoning. Fomepizole is a competitive inhibitor of alcohol dehydrogenase, the enzyme that catalyzes the initial steps in the metabolism of ethylene ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 InhibitorsFinasteride
go.drugbank.com/drugs/DB01216ApprovedInvestigationalFinasteride is an orally active drug that was first approved by the FDA in 1992 for the treatment of benign prostatic hyperplasia to improve symptoms and reduce the risk for acute urinary retention or
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesKetamine
go.drugbank.com/drugs/DB01221ApprovedInvestigationalVet approvedKetamine is an NMDA receptor antagonist with a potent anesthetic effect.[A31869] It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories.
Categories: NMDA Receptor Antagonists, Cytochrome P-450 SubstratesQuetiapine
go.drugbank.com/drugs/DB01224ApprovedInvestigationalInitially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of a...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSaquinavir
go.drugbank.com/drugs/DB01232ApprovedInvestigationalSaquinavir is an HIV-1 protease inhibitor used in combination with ritonavir and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the ...
Categories: P-glycoprotein inducers, P-glycoprotein inhibitorsChlorprothixene
go.drugbank.com/drugs/DB01239ApprovedInvestigationalWithdrawnChlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.
Categories: P-glycoprotein inhibitors, Dopamine D2 Receptor AntagonistsGemfibrozil
go.drugbank.com/drugs/DB01241ApprovedInvestigationalGemfibrozil is a fibric acid agent, similar to clofibrate, used to treat Type IIb, IV, and V hyperlipidemias. Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet,...
Categories: Peroxisome Proliferator Receptor alpha Agonist, Peroxisome Proliferator-activated Receptor alpha AgonistsBepridil
go.drugbank.com/drugs/DB01244ApprovedWithdrawnA long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activi...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates